PUBLISHER: Polaris Market Research | PRODUCT CODE: 1463096
PUBLISHER: Polaris Market Research | PRODUCT CODE: 1463096
U.S. AI In Oncology Market Share, Size, Trends, Industry Analysis Report, By Component (Software Solutions, Hardware, Services); By Cancer Type; By Treatment Type; Segment Forecast, 2024- 2023
The U.S. AI In oncology market size is expected to reach USD 7,710.88 million by 2032, according to a new study by Polaris Market Research. The report "U.S. AI In Oncology Market Share, Size, Trends, Industry Analysis Report, By Component (Software Solutions, Hardware, Services); By Cancer Type; By Application; By End-Use; Segment Forecast, 2024 - 2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.
The AI in oncology in the United States is driven by several factors, including the need for more precise and personalized cancer treatments, the growing volume of medical data, and the desire to improve patient outcomes and reduce healthcare costs. As cancer diagnosis and treatment become increasingly complex, AI technologies offer opportunities to revolutionize oncology practice and contribute to driving the market in the US.
In the US market, AI is spearheading a revolutionary transformation in the field of oncology by harnessing extensive datasets derived from multi-omics analyses, complemented by advancements in deep learning and high-performance computing. This seamless integration of AI technology into oncology is revolutionizing various facets of cancer management, spanning from detection and screening to diagnosis and classification.
AI plays a pivotal role in deciphering cancer genomics, scrutinizing the intricacies of the tumor microenvironment, evaluating prognostic and predictive biomarkers, and devising tailored strategies for post-diagnostic care and drug discovery. By deploying AI algorithms across these critical domains, healthcare practitioners are empowered to make more precise and informed decisions, ultimately enhancing the effectiveness and efficiency of cancer research and treatment. The comprehensive application of AI in oncology represents a significant leap forward in our ability to combat cancer, offering unprecedented insights and capabilities that hold immense promise for improving patient outcomes and advancing the frontier of oncological science in the United States.
Technological advancements are driving substantial growth potential, especially in sectors prioritizing precision, safety, and automation. Within this dynamic environment, artificial intelligence (AI) emerges as a transformative force, poised to revolutionize oncology screening practices. With its unparalleled ability to analyze vast amounts of data with exceptional accuracy and speed, AI holds the promise of significantly improving screening rates in oncology. By leveraging sophisticated algorithms and machine learning techniques, AI can detect subtle patterns and anomalies indicative of cancerous growths at earlier stages than traditional methods, thereby enhancing the effectiveness of screening programs.
Recognizing the transformative potential of AI in oncology, both public and private entities are intensifying their focus on investing in research and development (R&D) initiatives aimed at advancing AI-based screening products. These investments span a wide spectrum, encompassing the refinement of AI algorithms, the development of innovative imaging technologies, and the creation of integrated diagnostic platforms that seamlessly integrate AI into clinical workflows.
U.S. AI In Oncology Market Report Highlights
In 2023, the breast cancer segment accounted for the largest market share in U.S. A.I. in the oncology market. The increasing incidence of breast cancer among individuals has spurred a heightened demand for technologically advanced products within the market.
In 2023, the chemotherapy segment accounted for the largest market share due to its established status, broad applicability, clinical experience, continued innovation, and integration with A.I. technologies in the United States.
The key market players In the U.S. market are ConcertAI, Azra A.I., Digital Diagnostics Inc., IBM, G.E. HealthCare, Intel Corporation, NVIDIA Corporation, PathAI, and more.
Polaris Market Research has segmented the U.S. AI in oncology market report based on component, cancer type, treatment type.
U.S. AI In Oncology, Component Outlook (Revenue - USD Million, 2019 - 2032)
- Software Solutions
- Hardware
- Services
U.S. AI In Oncology, Cancer Type Outlook (Revenue - USD Million, 2019 - 2032)
- Breast Cancer
- Lung Cancer
- Prostate Cancer
- Colorectal Cancer
- Brain Tumor
- Others
U.S. AI In Oncology, Treatment Type Outlook (Revenue - USD Million, 2019 - 2032)
- Chemotherapy
- Radiotherapy
- Immunotherapy
- Others
Table of Contents
1. Introduction
- 1.1. Report Description
- 1.1.1. Objectives of the Study
- 1.1.2. Market Scope
- 1.1.3. Assumptions
- 1.2. Stakeholders
2. Executive Summary
- 2.1. Market Highlights
3. Research Methodology
- 3.1. Overview
- 3.1.1. Data Mining
- 3.2. Data Sources
- 3.2.1. Primary Sources
- 3.2.2. Secondary Sources
4. U.S. AI In Oncology Market Insights
- 4.1. U.S. AI In Oncology Market - Industry Snapshot
- 4.2. U.S. AI In Oncology Market Dynamics
- 4.2.1. Drivers and Opportunities
- 4.2.1.1. Increasing prevalence of cancer patient
- 4.2.1.2. Continuous improvement and expansion of healthcare infrastructure
- 4.2.2. Restraints and Challenges
- 4.2.2.1. Regulatory Challenges are likely to impede the market growth
- 4.2.1. Drivers and Opportunities
- 4.3. Porter's Five Forces Analysis
- 4.3.1. Bargaining Power of Suppliers (Moderate)
- 4.3.2. Threats of New Entrants: (Low)
- 4.3.3. Bargaining Power of Buyers (Moderate)
- 4.3.4. Threat of Substitute (Moderate)
- 4.3.5. Rivalry among existing firms (High)
- 4.4. PESTLE Analysis
- 4.5. U.S. AI In Oncology Industry trends
- 4.6. Value Chain Analysis
- 4.7. COVID-19 Impact Analysis
5. U.S. AI In Oncology Market, by Component
- 5.1. Key Findings
- 5.2. Introduction
- 5.2.1. U.S. AI In Oncology, by Component, 2019-2032 (USD Million)
- 5.3. Software Solutions
- 5.3.1. U.S. AI In Oncology Market, by Software Solutions, 2019-2032 (USD Million)
- 5.4. Hardware
- 5.4.1. U.S. AI In Oncology Market, by Hardware, 2019-2032 (USD Million)
- 5.5. Services
- 5.5.1. U.S. AI In Oncology Market, by Services, 2019-2032 (USD Million)
6. U.S. AI In Oncology Market, by Cancer Type
- 6.1. Key Findings
- 6.2. Introduction
- 6.2.1. U.S. AI In Oncology Market, by Cancer Type, 2019-2032 (USD Million)
- 6.3. Breast Cancer
- 6.3.1. U.S. AI In Oncology Market, by Breast Cancer, 2019-2032 (USD Million)
- 6.4. Lung Cancer
- 6.4.1. U.S. AI In Oncology Market, by Lung Cancer, 2019-2032 (USD Million)
- 6.5. Prostate Cancer
- 6.5.1. U.S. AI In Oncology Market, by Prostate Cancer, 2019-2032 (USD Million)
- 6.6. Colorectal Cancer
- 6.6.1. U.S. AI In Oncology Market, by Colorectal Cancer, 2019-2032 (USD Million)
- 6.7. Brain Tumor
- 6.7.1. U.S. AI In Oncology Market, by Brain Tumor, 2019-2032 (USD Million)
- 6.8. Others
- 6.8.1. U.S. AI In Oncology Market, by Others, 2019-2032 (USD Million)
7. U.S. AI In Oncology Market, by Treatment Type
- 7.1. Key Findings
- 7.2. Introduction
- 7.2.1. U.S. AI In Oncology Market, by Treatment Type, 2019-2032 (USD Million)
- 7.3. Chemotherapy
- 7.3.1. U.S. AI In Oncology Market, by Chemotherapy, 2019-2032 (USD Million)
- 7.4. Radiotherapy
- 7.4.1. U.S. AI In Oncology Market, by Radiotherapy, 2019-2032 (USD Million)
- 7.5. Immunotherapy
- 7.5.1. U.S. AI In Oncology Market, by Immunotherapy, 2019-2032 (USD Million)
- 7.6. Others
- 7.6.1. U.S. AI In Oncology Market, by Others, 2019-2032 (USD Million)
8. Competitive Landscape
- 8.1. Expansion and Acquisition Analysis
- 8.1.1. Expansion
- 8.1.2. Acquisitions
- 8.2. Partnerships/Collaborations/Agreements/Exhibitions
11. Company Profiles
- 11.1. Azra AI
- 11.1.1. Company Overview
- 11.1.2. Financial Performance
- 11.1.3. Component Benchmarking
- 11.1.4. Recent Development
- 11.2. ConcertAI
- 11.2.1. Company Overview
- 11.2.2. Financial Performance
- 11.2.3. Component Benchmarking
- 11.2.4. Recent Development
- 11.3. Digital Diagnostics Inc.
- 11.3.1. Company Overview
- 11.3.2. Financial Performance
- 11.3.3. Component Benchmarking
- 11.3.4. Recent Development
- 11.4. GE HealthCare
- 11.4.1. Company Overview
- 11.4.2. Financial Performance
- 11.4.3. Component Benchmarking
- 11.4.4. Recent Development
- 11.5. IBM
- 11.5.1. Company Overview
- 11.5.2. Financial Performance
- 11.5.3. Component Benchmarking
- 11.5.4. Recent Development
- 11.6. Azra AI
- 11.6.1. Company Overview
- 11.6.2. Financial Performance
- 11.6.3. Component Benchmarking
- 11.6.4. Recent Development
- 11.7. ConcertAI
- 11.7.1. Company Overview
- 11.7.2. Financial Performance
- 11.7.3. Component Benchmarking
- 11.7.4. Recent Development
- 11.8. Digital Diagnostics Inc.
- 11.8.1. Company Overview
- 11.8.2. Financial Performance
- 11.8.3. Component Benchmarking
- 11.8.4. Recent Development
- 11.9. GE HealthCare
- 11.9.1. Company Overview
- 11.9.2. Financial Performance
- 11.9.3. Component Benchmarking
- 11.9.4. Recent Development
- 11.10. IBM
- 11.10.1. Company Overview
- 11.10.2. Financial Performance
- 11.10.3. Component Benchmarking
- 11.10.4. Recent Development
List of Tables
- Table 1 U.S. AI In Oncology Market, by Component, 2019-2032 (USD Million)
- Table 2 U.S. AI In Oncology Market, by Cancer Type, 2019-2032 (USD Million)
- Table 3 U.S. AI In Oncology Market, by Treatment Type, 2019-2032 (USD Million)
List of Figures
- Figure 1 U.S. AI In Oncology Market, 2019-2032 (USD Million)
- Figure 2 Integrated Ecosystem
- Figure 3 Research Methodology: Top-Down & Bottom-Up Approach
- Figure 4 Porter's Five Forces
- Figure 5 Market by Cancer Type
- Figure 6 U.S. AI In Oncology Market, by Cancer Type, 2021 & 2030 (USD Million)
- Figure 7 Market by Component
- Figure 8 U.S. AI In Oncology Market, by Component, 2021 & 2030 (USD Million)
- Figure 9 Market by Treatment Type
- Figure 10 U.S. AI In Oncology Market, by Treatment Type, 2021 & 2030 (USD Million)
- Figure 11 U.S. AI In Oncology Market Assessment, By Countries, 2019-2032 (USD Million)
- Figure 12 Strategic Analysis - U.S. AI In Oncology Market
